13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001958125
Total reported value
$532.1M
$532.1M
37 檔
33.0%
At the close of Q1 2025, Catalio Capital Management, LP disclosed equity holdings valued at approximately $532.1M, spread across 37 reported holdings.
During Q1 2025, Catalio Capital Management, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BDX | Becton Dickinson And Co | Stock-Healthcare | 11.36% | — | +37.24% | |
| 2 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 8.14% | — | -0.80% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 8.10% | -0.33% | +7.17% | |
| 4 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 7.68% | -0.30% | +30.75% | |
| 5 | ASND | Ascendis Pharma A/S | Stock-Other | 7.41% | -6.17% | EXIT | |
| 6 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.73% | -2.97% | EXIT | |
| 7 | VCYT | Veracyte Inc | Stock-Other | 5.50% | — | +55.38% | |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 5.18% | -0.10% | — | |
| 9 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.76% | — | — | |
| 10 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.40% | — | -1.11% | |
| 11 | LIVN | LivaNova PLC | Stock-Other | 3.65% | — | -25.52% | |
| 12 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.37% | -9.22% | — | |
| 13 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 3.33% | — | — | |
| 14 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.97% | +0.22% | +23.79% | |
| 15 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.80% | -4.04% | EXIT | |
| 16 | QURE | uniQure N.V. | Stock-Other | 2.14% | -1.68% | EXIT | |
| 17 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.89% | — | — | |
| 18 | ✓ | Soleno Therapeutics Inc | Stock-Other | 1.58% | — | — | |
| 19 | SEPN | Septerna Inc | Stock-Other | 1.44% | +1.89% | — | |
| 20 | TARA | Protara Therapeutic Inc | Stock-Other | 1.13% | -0.26% | — | |
| 21 | ADPT | Adaptive Biotechnologies | Stock-Other | 1.11% | -2.10% | EXIT | |
| 22 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.09% | — | — | |
| 23 | KROS | Keros Therapeutics Inc | Stock-Other | 0.97% | — | -4.40% | |
| 24 | VIR | Vir Biotechnology Inc | Stock-Other | 0.96% | — | — | |
| 25 | REPL | Replimune Group Inc | Stock-Other | 0.84% | — | — | |
| 26 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.57% | — | +57.68% | |
| 27 | OM | Outset Medical Inc | Stock-Other | 0.45% | +0.01% | — | |
| 28 | ✓ | Arcutis Biotherapeutics Inc | Stock-Other | 0.30% | — | — | |
| 29 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 30 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.17% | -0.03% | — | |
| 31 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 32 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 33 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.14% | +0.69% | — | |
| 34 | HYPR | Hyperfine Inc | Stock-Other | 0.13% | +0.03% | — | |
| 35 | ATAI | AtaiBeckley Inc. | Stock-Other | 0.07% | — | — | |
| 36 | GUTS | Fractyl Health Inc | Stock-Other | 0.06% | +0.39% | — | |
| 37 | SNSEEUR | Sensei Biotherapeutics Inc | Stock-Other | 0.03% | — | — |
According to official SEC Form 13F filings, Catalio Capital Management, LP reported a total U.S. public equity portfolio value of $532.1M across 37 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BDX, SWTXUSD, BBIO) accounted for 33.0% of total reported equity market value during Q1 2025.
During Q1 2025, Catalio Capital Management, LP's top holdings by market value included BDX (11.4%)、SWTXUSD (8.1%)、BBIO (8.1%). The largest single position, BDX, represented 11.4% of total portfolio value.
In Q1 2025, Catalio Capital Management, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.